Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL
Elise A Chong,Kingsley Gideon Kumashie,Emeline R Chong,Joseph Fabrizio,Aditi Gupta,Jakub Svoboda,Stefan K Barta,Kristy M Walsh,Ellen B Napier,Rachel K Lundberg,Sunita D Nasta,James N Gerson,Daniel J Landsburg,Joyce Gonzalez,Andrew Gaano,Madison E Weirick,Christopher M McAllister,Moses Awofolaju,Gavin N John,Shane C Kammerman,Josef Novaceck,Raymone Pajarillo,Kendall A Lundgreen,Nicole Tanenbaum,Sigrid Gouma,Elizabeth M Drapeau,Sharon Adamski,Kurt D’Andrea,Ajinkya Pattekar,Amanda Hicks,Scott Korte,Harsh Sharma,Sarah Herring,Justine C Williams,Jacob T Hamilton,Paul Bates,Scott E Hensley,Eline T Luning Prak,Allison R Greenplate,E John Wherry,Stephen J Schuster,Marco Ruella,Laura A Vella,Kurt D'Andrea
DOI: https://doi.org/10.1093/infdis/jiae106
2024-03-05
The Journal of Infectious Diseases
Abstract:Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. SARS-CoV-2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic mRNA vaccine response in retrospective and prospective cohorts with lymphoma and CLL, paired with clinical and research immune parameters. Reduced serologic response was observed more frequently during active therapies, but non-response was also common within observation and post-treatment groups. Total IgA and IgM correlated with successful vaccine response. In individuals treated with CART-19, non-response was associated with reduced B and T follicular helper cells. Predictors of vaccine response varied by disease and therapeutic group, and therefore further studies of immune health during and after cancer therapies are needed to allow individualized vaccine timing.
immunology,infectious diseases,microbiology